Answers are grounded in this paper and cite their sources.
Retrospective study classifies growth hormone-secreting tumors in patients with acromegaly, suggesting new diagnostic criteria.
Background: Acromegaly/gigantism is a rare disease primarily caused by growth hormone (GH)-secreting pituitary neuroendocrine tumors (PitNETs). With the update in the WHO 5th edition classification of pituitary tumors, particularly the introduction of the novel PIT1/SF1 co-expressing tumor subtype, our understanding of these neoplasms has significantly advanced. However, systematic pathological classification and clinical characterization studies of GH-secreting PitNETs remain relatively scarce. Methods: A retrospective study was conducted on 143 patients with acromegaly/gigantism who underwent surgical treatment at Peking Union Medical College Hospital between June 2022 to December 2024. Tumor specimens were re-evaluated for pathological subtyping. Demographic data, radiological characteristics, hormone profiles, immunohistochemical findings, and clinical outcomes were collected and compared among subtypes. Results: 45 cases (32%) were classified as pure GH-secreting tumors, while the remainder showed co-expression of other hormones and transcription factors. Among PIT1-lineage tumors, sparsely granulated somatotroph tumors (SGST) demonstrated greater cavernous sinus invasion, larger maximal tumor diameter, lower GH secretion index and immunostaining intensity, and reduced SSTR2 expression, suggesting a more aggressive biological behavior. Co-expression of prolactin (PRL) increased the risk of hyperprolactinemia (OR = 2.843), though only 23.7% of mammosomatotroph tumors (MST) and 32.6% of mixed somatotroph–lactotroph tumors (MSLT) presented with hyperprolactinemia. Additionally, 19 PIT1/SF1 co-expressing tumors were identified, showing diverse hormonal profiles and significantly higher cavernous sinus invasion compared to PIT1-lineage tumors. Conclusion: GH-secreting PitNETs exhibit marked heterogeneity in pathological subtypes. Current classification systems require clearer cutoff criteria to improve diagnostic consistency. SGSTs are associated with a more invasive phenotype, warranting close clinical monitoring and long-term follow-up. PIT1/SF1 co-expressing tumors represent a distinct and heterogeneous entity that should be considered in future classification frameworks.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: